SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Noven Pharmaceuticals (NOVN)
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: tktom who wrote (47)6/26/1999 5:42:00 PM
From: zizzerzazzer  Read Replies (1) of 66
 
A study presented at the 81st Annual Meeting of the Endocrine Society this week has positive implications for Noven's Combipatch. The presentations occurred from June 12 to 15 in San Diego. Results were reported of a four-year placebo-controlled double-blind trial that involved 1,609 women in the U.S. and Great Britain with normal bone mineral density (BMB). The study showed that one of two forms of hormone replacement therapy (HRT) regimens produced dramatic results in treating osteoporosis. The study compared Merck's Fosamax (alendronate), the first non-hormonal drug for the treatment of osteoporosis that generated $775 million in revenue in 1998, in combination with two HRT regimens. The American HRT regimen included American Home Products' Premarin and Pharmacia Upjohn's Provera (estrogen and medroxyprogesterone acetate-MPA), same as PremPro/PremPhase; the European regimen included estradiol and norethindrone acetate-NETA, same as CombiPatch. The study reported that those taking Fosamax alone experienced an average 3% increase in BMD, those taking Fosomax and the American HRT regimen experienced an average 4.5% increase in BMD, while those taking Fosamax and the European HRT (Combipatch equivalent) experienced an average 7% increase in BMD. The study is one of the first that critically evaluates BMD effects of two different HRT regimens for osteoporosis. It may lead to wider use of CombiPatch in treating osteoporosis. Source: Fahnestock & Company.
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News